Great news, at BioCity based Sygnature Discovery we’re further strengthening our oncology and immuno-oncology capabilities with the acquisition of Alderley Oncology, a focused in vivo pharmacology service provider which undertakes high quality in vivo services for cancer drug discovery. The acquisition will add significant in-house expertise at Sygnature in...
BioCity, Nottingham based XenoGesis has been selected by LUNAC Therapeutics Limited to support them in the discovery of novel anticoagulant therapies that have a reduced risk of bleeding compared to current therapies. LUNAC has been assisted in the selection process by the Medicines Discovery Catapult. LUNAC...
THE Northern Health Science Alliance (NHSA) today welcomes three new directors to take forward the organisation into the next stage of its development as a world-leading cluster organisation across the North’s life sciences. Professor Sir John Tooke, Dr Kath Mackay and Dr Jonathan Sheffield OBE have...
BioCity client company Phenotypeca, are delighted to announce a positive first-quarter result in the Innovate UK funded project, developing next-generation baker’s yeast production strains for BioCity, Glasgow based Invizius’ novel H-Guard coating for dialysis membranes. These will be capable of preventing, at source, the blood's...
BioCity based XenoGesis’ Global Head of Business Development, Dr Rachel Hemsley has joined the University of Oxford’s Medical Sciences Experts in Residence (ExIR) scheme. The Experts in Residence programme is managed by the Medical Science Division’s Translational Research Office, Business Development & Partnering team and Oxford University Innovation. It aims to...
MediCity, Nottingham based Locate Bio Ltd (“Locate”), an orthobiologics company pursuing multiple high value spinal opportunities, today announces that John von Benecke has been appointed CEO to drive Locate’s lead program for spinal fusion and continue to build out its spinal pipeline. John von Benecke has...
Supporting the discovery and development of new therapeutics during the pandemic Nottingham-based contract research organisations (CROs) have strengthened their existing links to work together and support the discovery and development of new therapeutics during the pandemic. Many businesses have been impacted by the restrictions on the movement...
Article courtesy of Building Better Healthcare ILC Therapeutics believes Interferon, Alpha 14, could reduce reliance on ventilators and prevent the onset of fatal lung condition. A UK-based biotechnology firm has announced the discovery of two separate novel treatments for COVID-19 patients before they are put on ventilators. The...
BioCity 2019 Accelerator programme graduate company, Myndr, has secured six-figure funding from the government’s business innovation programme. Myndr, which is based in Newcastle, has received £300k investment from Innovate UK to expand its proposition. Founded by Lizzy Hodcroft and Emma Reilly, Myndr aims to create an anonymous platform,...
Upperton Pharma Solutions, a UK-based contract development and manufacturing organisation (CDMO) have invested £500K in significantly expanding their tablet manufacturing capabilities with the addition of tablet processing equipment for wet granulation, roller compaction, tablet compression, hardness testing, dedusting, weight sorting and tablet coating throughout 2019...